For research use only. Not for use in humans.

Siplizumab (Anti-CD2)

Synonyms: LFA-2, SRBC

Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD.

Siplizumab (Anti-CD2)

Quality Control

Batch: A256201 Purity: 99% Protein concentration: 12.45mg/ml Endotoxin Level: <1EU/mg
99

Mechanism of Action

Description
Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD.

Product Details

CAS No. 288392-69-8
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06972069 RECRUITING Drug: Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Kidney Failure; Transplant Recipient (Kidney); Transplant Tolerance; Immunosuppresion; Immunosuppression After Kidney Transplantation Tatsuo Kawai, MD, PhD 2025-05-31 EARLY_PHASE1
NCT05900401 ACTIVE_NOT_RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab|Dru Kidney Failure; Kidney Transplant; Complications; Chimera Massachusetts General Hospital 2023-10-01 PHASE1; PHASE2
NCT07508787 RECRUITING Drug: Siplizumab|Drug: Rabbit anti-thymocyte globulin Renal Transplant Failure and Rejection Nefro Avillion Clinical Development, LLC 2026-06-29 PHASE2
NCT06455280 RECRUITING Drug: Siplizumab Autoimmune Liver Disease; Liver Transplant Disorder; Autoimmune Hepatitis; Primary Sclerosing Cholangitis; End Stage Liver DIsease; Cirrhosis, Liver Elizabeth C. Verna 2024-09-11 PHASE1
NCT06326476 RECRUITING Drug: Siplizumab Hidradenitis Suppurativa University of Alabama at Birmingham 2025-05-09 EARLY_PHASE1
NCT04540380 ACTIVE_NOT_RECRUITING Drug: Rituximab, Fludarabine, Cyclophosphamide, Thymic irrad Renal Failure Massachusetts General Hospital 2021-09-01 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-22)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.